MACROGENICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $15.69 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.19, a 15.28% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $19.11, a 20.34% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $23.99, a 9.00% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $22.01, a 4.02% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $22.06, a 14.06% decline from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $25.67, a 34.26% increase from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $19.12, a 16.03% decline from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $22.77.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.69 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $16.19 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $22.06 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $21.29 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $22.04 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $19.11 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $25.67 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $22.09 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $22.83 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $23.99 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $19.12 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $19.77 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $21.58 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $22.01 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $22.77 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $22.76 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $23.08 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $21.16 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |